DBV TechnologiesDBVT
About: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Employees: 106
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
9% less funds holding
Funds holding: 33 [Q1] → 30 (-3) [Q2]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
38.71% less ownership
Funds ownership: 69.75% [Q1] → 31.04% (-38.71%) [Q2]
53% less capital invested
Capital invested by funds: $28.8M [Q1] → $13.7M (-$15.1M) [Q2]
95% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 22
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
JMP Securities Jonathan Wolleben 54% 1-year accuracy 29 / 54 met price target | 609%upside $5 | Market Outperform Reiterated | 24 Sept 2024 |
HC Wainwright & Co. Andrew Fein 48% 1-year accuracy 76 / 157 met price target | 609%upside $5 | Buy Reiterated | 1 Aug 2024 |
JMP Securities Jonathan Wolleben 54% 1-year accuracy 29 / 54 met price target | 609%upside $5 | Market Outperform Maintained | 31 Jul 2024 |